TLDR Eli Lilly stock climbs after FDA approves weekly insulin drug Onswik Onswik offers a new weekly treatment option for type 2 diabetes patients FDA approval follows successful QWINT Phase
Eli Lilly and Company (LLY) shares climbed to $1,191.92, gaining 3.56%, after the FDA approved its weekly insulin treatment Onswik. The stock moved higher after breaking above the $1,150 area and approaching the $1,200 resistance zone. The approval strengthens Lilly’s diabetes portfolio with a new option designed for adults with type 2 diabetes.
The U.S. Food and Drug Administration approved Onswik, also known as insulin efsitora alfa-gobe, as a once-weekly basal insulin. The treatment is approved alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. Lilly said the drug provides steady basal insulin levels throughout a seven-day period.
The FDA decision marks the fourth global approval for Onswik after regulatory clearance in Europe, Mexico, and Japan. Therefore, the treatment has gained wider regulatory recognition across several major healthcare markets. Lilly developed Onswik to reduce the burden of daily insulin injections for eligible patients.
The approval followed results from the QWINT Phase 3 clinical program, which tested Onswik in more than 3,400 adults. The trials showed the weekly insulin achieved similar A1C reductions compared with daily insulin glargine and insulin degludec. Furthermore, the studies reported a safety profile comparable with existing daily basal insulin options.
The QWINT clinical program included four global registration studies that began in 2022. The trials evaluated Onswik across different groups of adults with type 2 diabetes. Additionally, researchers compared the treatment against commonly used daily insulin therapies.
QWINT-1 studied adults who had not previously used insulin and compared Onswik with insulin glargine. QWINT-2 compared the weekly treatment with insulin degludec among insulin-naive adults. The studies focused on measuring blood sugar improvements and treatment safety over extended periods.
Moreover, QWINT-3 and QWINT-4 examined patients already using basal insulin treatments. These trials compared weekly Onswik with daily insulin degludec and insulin glargine. The findings supported Lilly’s application for wider use among adults managing type 2 diabetes.
Lilly remains a major player in diabetes care, with insulin products serving millions of patients worldwide. The company continues developing treatments that address changing needs in diabetes management. Onswik adds a new delivery option as demand grows for simpler treatment methods.
Around one in eight Americans currently live with diabetes, with type 2 diabetes accounting for most cases. Globally, diabetes cases are expected to rise significantly by 2030. As a result, insulin treatments remain an important option for patients who need additional blood sugar control.
Onswik will become available in the United States in the coming months through Lilly’s KwikPen system. The product will launch in two concentrations, including 500 units per milliliter and 1,000 units per milliliter. Therefore, Lilly’s latest approval introduces a weekly insulin alternative into the U.S. diabetes treatment market.
The post Eli Lilly and Company (LLY) Stock: Rises After FDA Approves Weekly Insulin Drug appeared first on Blockonomi.
